NEO Stock — NeoGenomics, Inc.

NeoGenomics, Inc. (NEO)

Updated October 16, 2026.

NEO is a Stock. Total return is 19.3% over the past 26.9 years, 769.6 points behind SPY at 788.9%.

NeoGenomics operates a network of cancer-focused testing laboratories in the United States and the United Kingdom, providing diagnostic services including cytogenetics, molecular testing, flow cytometry, and immunohistochemistry to hospitals, oncologists, pathologists, pharmaceutical companies, and clinical laboratories. The company does not currently distribute to shareholders; it previously paid a special one-time distribution that is not expected to recur regularly. This company appeals to growth-oriented investors seeking exposure to cancer diagnostics and precision medicine rather than income-focused investors.

NEO performance versus SPY

Price and return data through 2026-10-16.

Total return is 19.3% over the past 26.9 years, 769.6 points behind SPY at 788.9%. Over the past year its total return — price change plus distributions reinvested — is 62.0%. Its deepest 1-year drawdown was 45.6%.

NEO key facts

Asset type

Stock

Asset class

Equity

Inception date

11/10/1999

Distribution frequency

None

Last close

$16.65 (as of 2026-10-16)

Market cap

$2,168,026,137

Average volume

2308887.0

Ex-dividend date

12/17/2020

Payment date

12/30/2020

Beta

1.784

Payout ratio

0.0%

Forward P/E

222.2222

EPS

$-0.39

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

NEO risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 45.6%.

Who may consider NEO — and who may not

It is a weaker fit for investors who need monthly cash flow (NEO does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on NEO

• All tickers starting with N

Tagged: Healthcare.

Frequently asked questions